AstraZeneca PLC (AZN)vsGyre Therapeutics Inc. (GYRE)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
GYRE
Gyre Therapeutics Inc.
$7.68
+4.49%
HEALTHCARE · Cap: $696.73M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 50282% more annual revenue ($58.74B vs $116.59M). AZN leads profitability with a 17.4% profit margin vs 4.3%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
GYRE
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for GYRE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 33.4% year-over-year
Earnings expanding 166.2% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth, EPS Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Profit Margin, Operating Margin. A P/E of 381.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a value stock while GYRE is a hypergrowth play — different risk/reward profiles.
GYRE carries more volatility with a beta of 6.40 — expect wider price swings.
GYRE is growing revenue faster at 33.4% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 39/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative therapies for rare and complex diseases. By utilizing a proprietary platform, Gyre accelerates the discovery and commercialization of precision treatments aimed at addressing significant unmet medical needs. The company's strong focus on scientific excellence and patient-centered outcomes, coupled with its advancing pipeline in gene therapy and precision medicine, positions Gyre for substantial growth within the competitive biopharmaceutical landscape. Through strategic partnerships and a commitment to research, Gyre is poised to make a meaningful impact on the lives of patients facing challenging health conditions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?